1.
ERJ Open Res
; 9(3)2023 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37143828
RESUMO
Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile. https://bit.ly/3SbisW3.